Barbone F P, Middleton S A, Johnson D L, McMahon F J, Tullai J, Gruninger R H, Schilling A E, Jolliffe L K, Mulcahy L S
The R. W. Johnson Pharmaceutical Research Institute, Drug Discovery Research, Raritan, New Jersey 08869, USA.
J Biol Chem. 1997 Feb 21;272(8):4985-92. doi: 10.1074/jbc.272.8.4985.
Mutagenesis of the erythropoietin receptor (EPOR) permits analysis of the contribution that individual amino acid residues make to erythropoietin (EPO) binding. We employed both random and site-specific mutagenesis to determine the function of amino acid residues in the extracellular domain (referred to as EPO binding protein, EBP) of the EPOR. Residues were chosen for site-specific alanine substitution based on the results of the random mutagenesis or on their homology to residues that are conserved or have been reported to be involved in ligand binding in other receptors of the cytokine receptor family. Site-specific mutants were expressed in Escherichia coli as soluble EBP and analyzed for EPO binding in several different assay formats. In addition, selected mutant proteins were expressed as full-length EPOR on the surface of COS cells and analyzed for 125I-EPO binding in receptor binding assays. Using these methods, we have identified residues that appear to be involved in EPO binding as well as other residues, most of which are conserved in receptors of the cytokine receptor family, that appear to be necessary for the proper folding and/or stability of the EPOR. We present correlations between these mutagenesis data and the recently solved crystal structure of the EBP with a peptide ligand.
促红细胞生成素受体(EPOR)的诱变可用于分析单个氨基酸残基对促红细胞生成素(EPO)结合的贡献。我们采用随机诱变和定点诱变来确定EPOR细胞外结构域(称为EPO结合蛋白,EBP)中氨基酸残基的功能。根据随机诱变的结果或与细胞因子受体家族其他受体中保守的或已报道参与配体结合的残基的同源性,选择用于定点丙氨酸取代的残基。定点突变体在大肠杆菌中表达为可溶性EBP,并以几种不同的检测形式分析其与EPO的结合。此外,将选定的突变蛋白表达为COS细胞表面的全长EPOR,并在受体结合试验中分析其与125I-EPO的结合。使用这些方法,我们确定了似乎参与EPO结合的残基以及其他残基,其中大多数在细胞因子受体家族的受体中是保守的,这些残基似乎是EPOR正确折叠和/或稳定性所必需的。我们展示了这些诱变数据与最近解析的EBP与肽配体的晶体结构之间的相关性。